logo-loader
viewMaxCyte Inc

MaxCyte doses first phase I patient

The dose-escalation study is taking place in the US

image of a t-cell
MCY-M11 is what’s known as a chimeric antigen receptor, or CAR therapy, which gives T-cells the new ability to target a specific protein.

MaxCyte PLC (LON:MXCT) said the first patient had been dosed with its experimental targeted treatment for cancer.

MCY-M11 is what’s known as a chimeric antigen receptor, or CAR therapy, which gives T-cells the new ability to target a specific protein.

T-cells are part of the immune system and circulate around our bodies, scanning for cellular abnormalities and infections.

Ovarian cancer targeted 

MCY-M11 is a mesothelin targeting CAR that will be used to treat ovarian cancer and peritoneal mesothelioma, which forms around the tissue lining of the womb.

A total of 15 women with relapsed or hard-to-treat forms of the disease will receive the drug, which is being assessed primarily for safety and whether it is well tolerated by those taking it.

"The initiation of patient dosing in our first clinical trial with our lead CAR therapeutic candidate is a significant milestone for MaxCyte, validating our streamlined manufacturing process for clinical use," said MaxCyte chief executive Doug Doerfler.

"We are extremely pleased to have very experienced investigators at two leading clinical centres conducting this study in solid tumours.

“We believe this clinical trial will further demonstrate the potential of our proprietary CARMA (CAR therapeutic) autologous cell-therapy platform to develop meaningful, targeted cell-based immune therapies."

 

Quick facts: MaxCyte Inc

Price: 120 GBX

AIM:MXCT
Market: AIM
Market Cap: £68.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular...

Proactive Research analyst Emma Ulker gives her view on the work MaxCyte Inc's (LON:MXCT) doing in the area of cell and gene therapy. MXCT has more than 80 licensed programmes including more than 45 licensed for clinical use. They've announced seven clinical/commercial partnership deals...

4 days, 11 hours ago

2 min read